Share 'Pipeline Update: Summit outlines clinical development plans for Utrophin modulator program for Duchenne'
First patient clinical trials of SMT C1100 expected to start H2 2013
Summit to showcase program at international scientific conference
Summit's Press Release:
Summit today outlines its future plans for the continued development of utrophin modulators for the treatment of DMD. Utrophin modulation is a disease modifying approach that has the potential to treat all genetic forms of DMD. Summit’s…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this